Monash antibodies, Adelaide protein gels
Thursday, 22 January, 2009
Monash University has signed a deal with Danish pathology and cancer diagnostics specialist Dako to develop monoclonal antibodies for cancer research and treatment.
The Monash Antibody Technologies Facility (MATF), opened in September last year, will develop high-affinity antibodies for what it called “global commercialisation opportunities”.
MATF director Alan Sawyer said in a statement that the collaboration was part of the facility’s vision to provide the international research and diagnostics community with the best reagents possible.
Meanwhile, the Adelaide Proteomics Centre has decided to adopt publicly listed Fluorotechnics’ range of 2D gels and dyes for protein detection.
The centre has also agreed to become Fluorotechnics’ Australian reference customer and promote the company’s gels in Australia and internationally.
Clogged 'drains' in the brain an early sign of Alzheimer’s
'Drains' in the brain, responsible for clearing toxic waste in the organ, tend to get...
World's oldest known RNA extracted from woolly mammoth
The RNA sequences are understood to be the oldest ever recovered, coming from mammoth tissue...
The voice of reason: natural language interfaces to transform lab informatics
In everyday life, voice interaction with technology can save time and reduce friction. The same...
